ENTX Nov 2024 2.500 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:52AM EDT. Market open.
| Previous close | 1.0000 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 1.2500 |
| Strike | 2.50 |
| Expiry date | 2024-11-15 |
| Day's range | 1.0000 - 1.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireEntera Bio Reports Q1 2024 Financial Results and Provides Business Updates
JERUSALEM, May 10, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended March 31, 2024. “Entera is off to a strong start in 2024 thanks to the growth strategy we implemented in 2023, expanding our N-Tab™ therapeutic pipeline with potential first in class oral GLP-2, GLP-1/glucagon and PTH(1-34) pep
ZacksAre Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
Here is how Arbutus Biopharma (ABUS) and Entera Bio Ltd. (ENTX) have performed compared to their sector so far this year.
ZacksEntera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade
The latest trading day saw Entera Bio Ltd. (ENTX) settling at $1.98, representing a -1% change from its previous close.
© 2024 Yahoo. All rights reserved.